STAT+: 7 burning questions about the FDA’s post-Overton future
WASHINGTON — The White House pulled its nomination of Heidi Overton for commissioner of the Food and Drug Administration on Tuesday evening, startling senators on the health committee and introducing new questions about the future of the FDA.
- Continue to STAT+ to read the full story….
- The user fees that fund the agency’s drug reviews need to be reauthorized, a process that may be complicated by Democrats’ sweeping midterm election wins.
- And leaders are confronting the rise of artificial intelligence in scientific research and push to compete with China’s biotech industry.
The FDA is on its third leader of this Trump administration, and whoever replaces Overton as nominee could be the fourth.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →